source
- Viridian data lift prospects for thyroid eye disease drugWhereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by analysts as much more competitive with Amgen’s Tepezza.BioPharma Dive · 3mo ago↗ source
- STAT+: Are analysts too quick to gloss over Lilly’s liver case?Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The ReadoutSTAT · 3mo ago↗ source
- STAT+: Pharmalittle: We’re reading about RFK Jr. targeting antidepressants, J&J pushing an IBD drug, and moreHHS Secretary Robert F. Kennedy Jr. announced initiatives to rein in prescribing of SSRIs, the most widely used antidepressantsSTAT · 3mo ago↗ source